Epizyme, Inc. (NASDAQ:EPZM) Expected to Report Quarterly Sales of $10.11 Million

Brokers expect Epizyme, Inc. (NASDAQ:EPZM – Get Rating) to report sales of $10.11 million for the current fiscal quarter, Zacks reports. Three analysts have made earnings estimates for Epizyme. The highest sales estimate is $10.74 million and the lowest is $9.60 million. Epizyme recorded sales of $13.01 million in the same quarter last year, suggesting a negative growth rate of 22.3% year over year. The company is expected to release its next quarterly earnings report on Monday, January 1.

On average, analysts expect Epizyme to record annual sales of $43.82 million for the current fiscal year, with estimates ranging from $41.00 million to $47.23 million. For next year, analysts expect the company to record sales of $77.23 million, with estimates ranging from $61.40 million to $91.96 million. Zacks Investment Research sales calculations are an average based on a survey of analysts who follow Epizyme.

Epizyme (NASDAQ:EPZM – Get Rating) last reported quarterly earnings data on Tuesday, May 10. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The company posted revenue of $8.70 million for the quarter, compared to $10.86 million expected by analysts. Epizyme had a negative net margin of 614.08% and a negative return on equity of 2,459.33%. During the same period of the previous year, the company posted an EPS of ($0.69).

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

EPZM has been the subject of a number of recent research reports. StockNews.com began covering Epizyme in a research note on Thursday. They set a “sell” rating for the company. Zacks Investment Research has downgraded Epizyme from a buy to a hold rating and has set a price target of $1.75 for the stock. in a report on Friday, March 4. Finally, HC Wainwright cut its price target on Epizyme from $8.00 to $6.00 and set a “buy” rating on the stock in a Friday, June 3 report.

A number of institutional investors and hedge funds have recently changed their EPZM holdings. Kraematon Investment Advisors Inc. acquired a new equity stake in Epizyme in the fourth quarter worth approximately $28,000. Pinnacle Wealth Planning Services Inc. bought a new position in Epizyme during the fourth quarter worth approximately $31,000. Landscape Capital Management LLC acquired a new stake in Epizyme in the fourth quarter at a value of $40,000. Bayesian Capital Management LP acquired a new stake in Epizyme in the fourth quarter worth $40,000. Finally, Arizona State Retirement System increased its stake in Epizyme shares by 94.1% in the first quarter. Arizona State Retirement System now owns 37,398 shares of the biopharmaceutical company valued at $43,000 after buying 18,134 additional shares last quarter. 76.45% of the shares are currently held by institutional investors.

The NASDAQ EPZM opened at $0.71 on Thursday. The stock has a 50-day moving average of $0.68 and a 200-day moving average of $1.60. The company has a market capitalization of $117.01 million, a price-earnings ratio of -0.33 and a beta of 1.30. Epizyme has a 1-year low of $0.41 and a 1-year high of $9.86.

About Epizyme (Get an evaluation)

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops and commercializes novel epigenetic drugs for patients with cancer and other diseases in the United States. The company offers tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma in adult and pediatric patients.

Featured articles

Get a Free Copy of Zacks’ Research Report on Epizyme (EPZM)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Epizyme right now?

Before you consider Epizyme, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Epizyme wasn’t on the list.

While Epizyme currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Sallie R. Loera